MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Design Therapeutics Inc

Gesloten

4.13 14.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.53

Max

4.17

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.1M

-18M

Werknemers

56

EBITDA

-3.7M

-20M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+133.52% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-63M

201M

Vorige openingsprijs

-10.59

Vorige sluitingsprijs

4.13

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jul 2025, 15:46 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Marktinformatie

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Winsten

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Marktinformatie

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Marktinformatie

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Acquisities, Fusies, Overnames

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Marktinformatie

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Marktinformatie

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Marktinformatie
Acquisities, Fusies, Overnames

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Marktinformatie

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Acquisities, Fusies, Overnames

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Acquisities, Fusies, Overnames

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Marktinformatie

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

133.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.5 USD  133.52%

Hoogste 12 USD

Laagste 5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.